Back to results
US 11,999,773 B2Granted
Anti-BCMA chimeric antigen receptors
AssigneeCartesian Therapeutics, Inc.
InventorsYi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
Life of this patent
Estimating the term…
Abstract
Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
Claims10
A protein comprising an antigen-binding portion, wherein the antigen-binding portion is an anti-B-Cell Maturation Antigen (BCMA) binding domain comprising:
- a heavy chain complementarity determining region 1 (CDRH1) comprising any one of SEQ ID NOs:
- 1-3;
- a heavy chain complementarity determining region 2 (CDRH2) comprising any one of SEQ ID NOs:
- 4-6;
- a heavy chain complementarity determining region 3 (CDRH3) comprising any one of SEQ ID NOs:
- 7-9;
- a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO:
- 11;
- a light chain complementarity determining region 2 (CDRL2) comprising any one of SEQ ID NOs:
- 12-15;
- and
- a light chain complementarity determining region 3 (CDRL3) comprising any one of SEQ ID NOs:
- 16-18.
10 more elements
Dependencies are inferred from the claim text.